Important Safety Information
EXJADE is available by prescription only.
What is the most important safety information to know about EXJADE?
EXJADE may cause serious kidney problems, liver problems, and bleeding in the stomach or intestines. In some cases, these problems were fatal.
These problems occurred more often in elderly patients, patients with high-risk myelodysplastic syndromes, pre-existing kidney or liver problems, or low blood counts.
EXJADE may also cause serious liver problems. In some cases, these problems were fatal. These problems occurred more often in patients greater than 55 years of age.
Your doctor should check your kidneys with a blood test called serum creatinine and/or creatinine clearance:
- Before taking EXJADE
- Monthly during treatment
If you already have kidney problems or are at risk for kidney problems your doctor should check your kidneys:
- Every week for the first month
- Monthly during treatment
Your doctor should check your liver with blood tests called serum transaminases and bilirubin:
- Before taking EXJADE
- Every other week for the first month after starting EXJADE
- Monthly during treatment
Please see additional Important Safety Information, including Boxed WARNING.
Please see accompanying Full Prescribing Information.

Importance of Continuing Therapy
EXJADE works by attaching to the extra iron. Getting rid of the extra iron happens slowly over time with daily treatment. That is why you should always take EXJADE once a day on an empty stomach and wait at least 30 minutes before eating as prescribed by your doctor.
It is important to continue taking EXJADE until your doctor says you can safely stop taking the medication. Stopping EXJADE too soon might mean that not enough iron will be removed. It is also important to continue having your iron (or serum ferritin) levels monitored. That way you and your doctor know when and for how long you will need to take EXJADE.
If you are taking EXJADE, ask your doctor how long you might need to take your medication.
or call 1-800-282-7630 for information on the Novartis Pharmaceuticals Corporation Patient Assistance Program (PAP).

